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Bactofencin A, a New Type of Cationic Bacteriocin with Unusual
Immunity
Eileen F. O’Shea,a,c Paula M. O’Connor,a,c Orla O’Sullivan,a Paul D. Cotter,a,c R. Paul Ross,a,c Colin Hillb,c
Teagasc Food Research Centre, Moorepark, Fermoy, County Cork, Irelanda; Department of Microbiology, University College Cork, Cork, Irelandb; Alimentary Pharmabiotic
Centre, Cork, Irelandc
ABSTRACT Bacteriocin production is an important probiotic trait of intestinal bacteria. In this study, we identify a new type of
bacteriocin, bactofencin A, produced by a porcine intestinal isolate Lactobacillus salivarius DPC6502, and assess its potency
against pathogenic species including Staphylococcus aureus and Listeria monocytogenes. Genome sequencing of the bacteriocin
producer revealed bfnA, which encodes the mature and highly basic (pI 10.59), 22-amino-acid defensin-like peptide. Matrix-
assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectral analysis determined that bactofencin A has a mo-
lecular mass of 2,782 Da and contains two cysteine residues that form an intramolecular disulfide bond. Although an ABC trans-
porter and transport accessory protein were also present within the bacteriocin gene cluster, a classical bacteriocin immunity
gene was not detected. Interestingly, a dltB homologue was identified downstream of bfnA. DltB is usually encoded within the dlt
operon of many Gram-positive bacteria. It is responsible for D-alanylation of teichoic acids in the cell wall and has previously
been associated with bacterial resistance to cationic antimicrobial peptides. Heterologous expression of this gene conferred bac-
tofencin A-specific immunity on sensitive strains of L. salivarius and S. aureus (although not L. monocytogenes), establishing its
role in bacteriocin immunity. An analysis of the distribution of bfnA revealed that it was present in four additional isolates de-
rived from porcine origin and absent from five human isolates, suggesting that its distribution is host specific. Given its novelty,
we anticipate that bactofencin A represents the prototype of a new class of bacteriocins characterized as being cationic, with a
DltB homologue providing a cognate immunity function.
IMPORTANCE This study describes the identification, purification, and characterization of bactofencin A, a novel type of bacterio-
cin produced by L. salivarius DPC6502. Interestingly, bactofencin A is not similar to any other known bacteriocin but instead
shares similarity with eukaryotic cationic antimicrobial peptides, and here, we demonstrate that it inhibits two medically signifi-
cant pathogens. Genome sequence analysis of the producing strain also revealed the presence of an atypical dltB homologue in
the bacteriocin gene cluster, which was lacking a classical bacteriocin immunity gene. Furthermore, cloning this gene rendered
sensitive strains resistant to the bacteriocin, thereby establishing its role in providing cognate bacteriocin immunity. Four addi-
tional L. salivarius isolates, also of porcine origin, were found to contain the bacteriocin biosynthesis genes and successfully pro-
duced bactofencin A, while these genes were absent from five human-derived strains investigated.
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The genus Lactobacillus consists ofmore than 145 species whosehabitats range from soil and plants to the mammalian gastro-
intestinal tract (GIT) (1). These bacteria produce a rich diversity
of bacteriocins in terms of structure and mode of action, varying
from extensively posttranslationally modified lantibiotics such as
plantaricin C (2) to large, unmodified, heat-labile proteins such as
helveticin J (3).
Lactobacillus salivarius is a species particularly associated with
the mammalian GIT (4–7), and many associated probiotic attri-
butes, including favorable immunomodulatory, antiinflamma-
tory, and antiinfective properties, have been associated with spe-
cific strains (8). Indeed, due to its positive immunomodulatory
and potent antimicrobial activity, one strain of L. salivarius was
among six strains chosen to formulate amultispecies probiotic for
combating disease in critically ill patients (9). The L. salivarius
component of another five-strain probiotic combination, L. sali-
varius DPC6005, outcompeted four coadministered strains to
dominate within the porcine ileal digesta and mucosa (10). In
addition, the antistaphylococcal activity of L. salivarius CECT
5713, isolated from amother and child pair (7), indicated that this
strain is an alternative to conventional antibiotics in the treatment
of infectious mastitis in women during lactation (11, 12). Further
studies with this strain have highlighted its immune-modulatory
properties and its safety with respect to human consumption (13–
15).
The range of bacteriocins produced by L. salivarius extends
from the class IIa pediocin-like bacteriocinsOR-7 and L-1077 (16,
17) to the two-component class IIb bacteriocins abp118, salivari-
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cin P, salivaricin T, and variants (4, 18–23) and the class IId linear
non-pediocin-like bacteriocins, such as salivaricin B and salivari-
cin L (24, 21). Each of these bacteriocins has demonstrated inhib-
itory activity toward medically significant pathogens. Notably,
purified bacteriocin OR-7 and L-1077 have provided in vivo pro-
tection against Campylobacter jejuni and Salmonella enterica sero-
var Enteritidis infection in chickens (16, 17).Moreover, Corr et al.
demonstrated abp118-mediated protection against Listeriamono-
cytogenes infection in mice upon administration of the producing
strain L. salivariusUCC118, thereby substantiating the role of bac-
teriocins in mediating a probiotic effect (61). It is feasible that
these bacteriocins could be exploited for the therapeutic manipu-
lation of the intestinal flora. Indeed, the influence of abp118 on
the composition of the gut flora of diet-induced obese (DIO)mice
and pigs following the administration of the producing strain has
also been demonstrated recently (25, 26).
In this study, we describe an unusual bacteriocin, bactofencin
A, produced by the porcine intestinal isolate L. salivarius
DPC6502. The bacteriocin locus encodes a highly basic antimicro-
bial peptide of just 22 amino acid residues, and in this respect,
bactofencin A bears a close resemblance to certain eukaryotic cat-
ionic antimicrobial peptides. Moreover, a DltB homologue con-
fers on the producing strain specific immunity to bactofencin A,
suggesting a role for teichoic acid in the immunity mechanism.
Genes encoding this bacteriocin have been identified in several
porcine isolates but appear to be absent from human L. salivarius
isolates.
RESULTS
The isolation of L. salivariusDPC6502, which has broad-spectrum
antimicrobial activity, from porcine jejunal digesta has been de-
scribed previously (27). While PCR assays initially suggested that
this strain produces a variant of abp118, recent array-based com-
parative genomic hybridization (aCGH) analyses revealed the ab-
sence of abp118-related homologues in strain DPC6502 (21). In-
deed, this strain was the most divergent of seven L. salivarius test
strains when compared with the genome of the reference strain
L. salivarius UCC118 (28), exhibiting just 78% conservation of
strain UCC118-specific gene content (21). Its potent antimicro-
bial activity and considerable genetic divergence led to the further
characterization of strain DPC6502 and the associated antimicro-
bial activity.
Characterization of the antimicrobial phenotype of L. sali-
varius DPC6502. The peptide responsible for the antimicrobial
activity of L. salivarius DPC6502 was purified from an overnight
culture of the strain using cation exchange followed by reversed-
phase chromatography. Subsequent matrix-assisted laser desorp-
tion ionization–time of flight mass spectrometry (MALDI-TOF
MS) analysis revealed an associated mass of 2,782 Da in the active
fractions (Fig. 1). Edman analysis revealed the N-terminal se-
quence KRKXHRXRVYNNGMPTGMYRYM, where “X” at posi-
tions 4 and 7 indicates blank cycles for which no amino acid de-
rivative was detected. A homology search did not identify any
similar sequences in protein databases. The purified bacteriocin
peptide inhibited closely related lactobacilli, as well as Staphylo-
coccus aureus and, to a lesser extent, Listeria innocua (Fig. 1).
Considering the unusual nature of this bacteriocin, the ge-
nome of the producing strain L. salivarius DPC6502 was se-
quenced to identify the corresponding gene cluster.
Characterization of the bacteriocin locus in the genome of
L. salivarius DPC6502. Scanning of the entire draft genome se-
quence for a gene corresponding to the N-terminally derived
amino acid sequence revealed a chromosomally located open
reading frame (ORF),DLSL_0050, present on a gene clusterwhich
was absent from the publically available L. salivarius genome se-
quences. The unidentified amino acids at positions 4 and 7 in the
sequence determined by Edman degradation were, on the basis of
the corresponding codons, found to be lysine and cysteine resi-
dues, respectively (Fig. 2). The bacteriocin structural gene consists
of 159nucleotides and is predicted to encode a 53-amino-acid (aa)
precursor peptide comprised of a 31-aa double-glycine leader se-
quence and a 22-aa propeptide sequence which differed from that
FIG 1 HPLC profile (A), MALDI-TOF MS data (B), and antimicrobial ac-
tivity (C) of purified bactofencin A. WVL, wavelength.
O’Shea et al.
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derived by peptide sequencing with respect to the two most
C-terminally located residues (Fig. 2). The predicted mass of the
mature translation product (2,785 Da) differed from that deter-
mined by MALDI-TOF MS analysis of the active peptide
(2,782 Da) by 3 Da. MS analysis revealed an increase of 2 Da
(2,784 Da) in the mass of the active peptide when the cysteine
residues were in a reduced state (after treatment with dithreitol
[DTT] and iodoacetamide), indicating that an intramolecular di-
sulfide bond is formed between Cys7 and Cys22. A search of the
BLAST database did not identify any homologues for this ORF,
indicating that this peptide is unlike any previously characterized
bacteriocins. However, a search of the antimicrobial peptide da-
tabase (29) revealed that bactofencin A shares the greatest similar-
ity (42%) with a plant antimicrobial peptide (AMP) isolated from
extracts of the seed of Impatiens balsamina (Ib-AMP3) which dis-
plays both antibacterial and antifungal properties (30). In conse-
quence of the greater similarity of this bacteriocin to cationic pep-
tides of eukaryotic origin, it was designated bactofencinA.Despite
its similarity to Ib-AMP3, neither L. salivarius DPC6502 nor the
purified bactofencin A peptide exhibited antifungal activity
against the indicator strains investigated (data not shown).
TheORF immediately downstream from the bacteriocin struc-
tural gene (bfnA) encodes a putative product of 396 aa which
shares 74% identity with an operon-encoded D-alanyl transfer
protein (DltB) of Pediococcus pentosaceus ATCC 25745 (accession
no. YP_805052) and 65% identity with the operon-encoded DltB
of L. salivarius UCC118 (LSL_0891). DltB is a transmembrane
protein responsible for the transfer of activated D-alanine across
the cytoplasmic membrane, which is indispensable for the
D-alanyl esterification of teichoic acids (31, 32). Interestingly,
D-alanylation of teichoic acids has previously been found to con-
tribute to bacterial resistance to cationic antimicrobial peptides
due to the resultant reduction in the net negative charge generated
in the bacterial cell wall, thereby attenuating essential electrostatic
interactions (32–36). A second DltB-encoding gene
(DLSL_0976), present in a dlt operon (DLSL_0974 to
DLSL_0978), is also located on the chromosome of L. salivarius
DPC6502, the product of which shares 99% identity with DltB of
UCC118 (encoded by LSL_0891) and 65% identity with the de-
duced protein product of DLSL_0051. The ORFs downstream
from the dltB homologue encode a putative bacteriocin ABC
transporter (DLSL_0052) and a bacteriocin transport accessory
protein (DLSL_0053). The deduced protein sequence of the ABC
transporter contains an N-terminal peptidase C39 domain of
139 aa which contains a conserved cysteine motif and histidine
motif characteristic of the putative catalytic site responsible for the
cleavage of double-glycine leader sequences (37, 38). Thus, these
genes encode proteins which are probably responsible for the pro-
cessing and secretion of mature active bactofencin A. This puta-
tive bacteriocin transport system likely completes the bacteriocin
gene cluster (approximately 4 kb), as the adjacentORFs, which are
conserved in UCC118 (LSL_0035 to LSL_0042), display similarity
to the WalRK (YycGF) regulon responsible for the regulation of
bacterial cell wall metabolism of low-GC Gram-positive bacte-
ria (39).
Bactofencin A is active at micromolar concentrations. The
identification of the structural gene and deduced peptide se-
quence facilitated the production of synthetic bactofencin A. MS
analysis revealed a mass of 2,784 Da for the synthetic form of the
peptide, which displayed anti-Listeria and anti-S. aureus activity
that was similar to that of the purified natural bactofencin A pep-
tide (data not shown). This suggests that the disulfide bond of the
natural form of bactofencin A is not crucial for activity. In conse-
quence of this and of the fact that the synthetic approach provided
access to larger quantities of peptide, the synthetic bactofencin A
peptide was employed for further antimicrobial activity assays,
which on this occasion took the form of more-sensitive broth-
based MIC50 assays. These investigations revealed that, although
concentrations of up to 50 Mof synthetic bactofencin A did not
inhibit Escherichia coli, Cronobacter sakazakii, Salmonella, or any
of the fungal indicator strains employed, concentrations of 1 to
5 M were sufficient to inhibit the growth of both S. aureus
DPC5246 and L. monocytogenes NCTC 11994 by 50% (Fig. 3).
Furthermore, the bactericidal effect of bactofencin A was demon-
FIG 2 Nucleotide sequence and deduced peptide sequence of the structural
gene of bactofencin A. The leader sequence is underlined, and the GG-
processing site is indicated by an arrowhead. The bacteriocin structural gene
and predicted immunity gene and transport genes are indicated by black,
white, and gray arrows, respectively.
FIG 3 Inhibitory effect of synthetic bactofencin A on the growth of the
indicator strains L. monocytogenes NCTC 11994 (A) and S. aureus DPC5246
(B) at concentrations of 0 M (gray diamonds), 0.05 M (open circles),
0.1 M (black circles), 0.5 M (open squares), 1.0 M (), 5.0 M (open
trangles), and 10.0 M (black squares). Error bars represent standard devia-
tions based on triplicate data.
Bactofencin A, a Defensin-Like Bacteriocin
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strated by a 4-log reduction in viable S. aureus DPC5246 cells
following an 8-h incubation with the bacteriocin (Fig. 4).
A DltB homologue is responsible for bactofencin A-specific
immunity. Typically, the unmodified class II bacteriocin struc-
tural genes are cotranscribed with an ORF encoding a cognate
immunity protein, usually 50 to 150 aa in size and located down-
stream of the structural gene, which provides self-protection for
the producing strain. To determine whether the DltB homologue
encoded by theORF immediately downstreamof bfnA, designated
bfnI, has a role in bactofencin A immunity, an expression plasmid
(pEOS01) harboring bfnIwas constructed.When introduced into
the sensitive indicator strains L. monocytogenes NCTC11994 and
S. aureusDPC5246, a statistically significant increase in resistance
to bactofencin A, relative to the resistance of the corresponding
isogenic control strains harboring the pNZ44 plasmid, was evi-
dent for transformants of the S. aureus DPC5246 indicator strain
(Fig. 5) but not for those of the L. monocytogenes NCTC11994
strain (data not shown). Moreover, introducing the pEOS01 con-
struct into the more-similar, yet sensitive strain L. salivarius
UCC118 resulted in almost-complete immunity to the bacteriocin
for the corresponding transformants relative to the control
(Fig. 5B). However, this resistance was specific for bactofencin A,
as these clones did not exhibit enhanced resistance when exposed
to a range of cationic antimicrobial peptides, suggesting that the
protection provided is not due to a general impact on cell wall
charge (Fig. 6).
The results of cytochrome c binding assays also correlated with
these results. Cytochrome c is a highly positively charged protein
(pI 10), readily detected at 530 nm,whose binding is dependent on
the net negative cell surface charge. In a control study, following a
10-min exposure, the level of unbound cytochrome c detected in
the cell-free supernatant (CFS) of the dltA-deficient S. aureus
Sa113 mutant was considerably lower than the level in the CFS of
the wild-type strain. This indicates an increase in the net negative
cell surface charge of the mutant relative to that of the wild-type
FIG 4 Viability of S. aureus DPC5246 treated with (black squares) and with-
out (open circles) synthetic bactofencin A as a function of time. These results
represent the average of three independent experiments. Error bars represent
standard errors based on triplicate data.
FIG 5 (A) S. aureus DPC5246 containing pEOS01 exhibits significantly enhanced resistance to bactofencin A relative to the resistance of the isogenic control
strain at concentrations of 0.5 M (P  0.01), 2.5 M (P  0.05), and 5 M (P  0.05) following 24 h of incubation with the peptide. Error bars represent
standard deviations based on triplicate data. (B) L. salivarius UCC118 containing pEOS01 (ii) also exhibits enhanced resistance to bactofencin A relative to the
resistance of the respective isogenic control strain harboring pNZ44 (i).
O’Shea et al.
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strain, due to the associated decrease in D-alanylation of teichoic
acids (Fig. 7). However, the affinity for cytochrome c of S. aureus
DPC5246 or L. salivarius UCC118 containing pEOS01 did not
differ from that of the respective control (Fig. 7).
The bactofencin A locus is a novel hypervariable gene cluster
characteristic of L. salivarius of porcine origin. The production
of similar or identical bacteriocins is frequent among genetically
distinct strains or even species of lactic acid bacteria (LAB) (6,
40–42). Indeed, the genetic determinants for abp118-like bacte-
riocins are among the relatively high content of hypervariable
gene clusters of L. salivarius (6, 21, 43). To investigate whether the
bactofencin A locus described in this study is similarly among the
hypervariable loci of the flexible gene pool of L. salivarius, we
investigated eight additional L. salivarius isolates, four of human
and four of porcine intestinal origin (Table 1), for the presence of
the bactofencin A structural gene. A PCR product corresponding
to this gene could not be generated from the genomic DNA of the
four strains of human origin, namely, DPC6488, DPC6196,
DPC6107, and DPC6095. Cross-immunity assays also revealed
that each of these isolates was sensitive to the bactofencin
A-producing strain. However, all four additional porcine strains
(L. salivarius DPC6005, DPC6027, DPC6189, and 7.3) were im-
mune to bactofencin A and PCR positive for bfnA. Sequencing of
the PCR products generated confirmed 100% identity with the
bactofencin A structural gene of DPC6502 in each case. Subse-
quent purification andMS analysis confirmed bactofencin A pro-
duction in these strains.
DISCUSSION
Sequence analysis of the L. salivarius DPC6502 genome revealed
that the bactofencin A structural gene is encoded on a gene cluster
of approximately 4 kb which is not present in the well-
characterized L. salivarius UCC118 strain. While the leader se-
quence –VSRKDLAKVNGG of the bacteriocin prepeptide is un-
usually long (31 aa), it conforms with the consensus for double-
glycine leaders (as highlighted in boldface) (38). The fact that its
bioactivity did not require extensive posttranslational modifica-
tion of the peptide and the absence of the characteristic YGNGV
consensusmotif of pediocin-like class IIa bacteriocins suggest that
this peptide belongs to the diverse class IId bacteriocins of Gram-
positive bacteria (44). Class IId consists of a heterogenous collec-
tion of bacteriocins which cannot be assigned to any of the other
known bacteriocin subgroups. The mature bactofencin A peptide
is highly basic, containing eight positively charged residues that
are largely concentrated at theN terminus, whichmay be involved
inmediating the initial binding of the bacteriocin to target cells via
electrostatic interaction. Database searches have revealed that
this peptide does not share significant homology with previously
characterized bacteriocins but more closely resembles eukaryotic
antimicrobial peptides. It would thus appear that bactofencin A is
the first of a novel group of bacteriocins.
Although a previous assessment of the antimicrobial activity of
the producing strain, using agar well diffusion assays with neutral-
ized CFS, revealed a broad spectrum of inhibition which included
22 of 62 indicator strains (27), this activity was found to be pre-
dominantly against closely related strains of LAB. The availability
of purified bactofencin A in this study established the in vitro
efficacy of the bacteriocin, revealing MIC50 values of 1 to 5 M
against the pathogenic indicator strains L. monocytogenes and
S. aureus, as well as the bactericidal nature of this antimicrobial
activity. This activity is comparable to that of the two-component
lantibiotic lacticin 3147, which displayed aMIC50 of 7 to 8M for
the bovine mastitis isolate S. aureus DPC5245 (45). However, the
fact that bactofencinA is an unmodified bacteriocin and, thus, can
be readily generated in large quantities in a synthetic form may
make this novel bacteriocin a more-favorable alternative to anti-
biotics for animal husbandry-related applications.
Despite its uncharacteristically large size (396 aa) relative to the
sizes of cognate bacteriocin immunity proteins (30 to 100 aa), the
expression of bfnI enhanced the resistance of two sensitive indica-
tor species to bactofencin A, conferring almost-complete immu-
nity on L. salivarius UCC118. However, a statistically significant
increase in bactofencin A resistance was not observed for the
L. monocytogenes indicator strain, possibly due to the lower sensi-
tivity of this strain to the bacteriocin (Fig. 3A). BfnI shares con-
siderable homology with D-alanyl transfer proteins, which are
generally encoded on the dlt operon, responsible for the
D-alanylation of teichoic acids on the bacterial cell wall. Being
predominantly negatively charged, teichoic acids are conse-
quently a major determinant of the cell wall electrostatic interac-
tions. Increased D-alanylation of teichoic acids attenuates such
interactions, thereby conferring resistance to cationic antimicro-
bial peptides (32–36). Interestingly, S. aureus organisms harbor-
FIG 7 Comparison of relative net cell surface charge. The dltA-deficient
S. aureus Sa113 experimental control has a higher affinity for cytochrome c
than wild-type S. aureus Sa113 due to a decrease in D-alanylation of teichoic
acids and a resultant increase in the net negative cell surface charge. However,
the expression of BfnI does not influence the affinity of S. aureusDPC5246 or
L. salivariusUCC118 for cytochrome c relative to the affinities of their respec-
tive controls.
FIG 6 The specific immunity of L. salivarius UCC118 containing pEOS01 to
bactofencin A (ii) (b) relative to the resistance of L. salivarius UCC118 con-
taining pNZ44 (i) (b) was not extended to the additional cationic antimicro-
bial peptides investigated, gramicidin (a), protegrin-1 (c), magainin II (d), (e)
polymyxin B (e), -polylysine (f), and nisin (g).
Bactofencin A, a Defensin-Like Bacteriocin
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ing several copies of the dlt operon displayed decreased sensitivity
to various cationic antimicrobial peptides (32). However, the re-
sistance mediated by BfnI did not extend to a range of cationic
antimicrobials investigated but was exclusive for bactofencin A.
Therefore, despite the homology of BfnI to DltB proteins, these
results suggest that BfnI does not function to increase the content
of esterified D-alanyl of teichoic acids on the bacterial cell surface.
To our knowledge, this is the first report of a DltB homologue for
which a specific mechanism of bacteriocin immunity has been
reported.
The ability of genetically distinct strains and, in several cases,
distinct species to produce similar or identical bacteriocins is a
common phenomenon of LAB (6, 40–42). It is evident from the
results of this study that bactofencin A is among the hypervariable
gene clusters of L. salivarius and is perhaps exclusively associated
with those of porcine intestinal origin. The additional porcine
isolates investigated for bactofencin A production in this study
also produce a two-component class IIb bacteriocin, salivaricin
P (4). Bactofencin A production was previously undetected in
antimicrobial analyses of these strains, likely as a consequence of
its hydrophilic nature and the potent antimicrobial activity of
the coproduced salivaricin P (MIC50 of 50 nM for L. innocua
DPC5372) (4, 46). Notably, previous analyses revealed that both
of the bacteriocin-positive human isolates L. salivarius UCC118
and DPC6488 were sensitive to the antimicrobial activity of strain
DPC6005 (21), despite the considerable homology of the respec-
tive putative immunity proteins of abp118, salivaricin T, and sali-
varicin P produced by these strains. Thus, this was likely a conse-
quence of bactofencin A-mediated activity of strain DPC6005.
Furthermore, L. salivarius DPC6005 has also demonstrated a
competitive advantage within the porcine ileum (10) and was as-
sociated with reduced Salmonella shedding in pigs when adminis-
tered as part of a probiotic formulation (47). A combination of
bactofencin A and salivaricin P production likely contributed to
the superior probiotic properties demonstrated by this strain
within the porcine intestine.
In conclusion, a novel bacteriocinwith potent anti-Listeria and
anti-S. aureus activity has been identified in L. salivarius. Genomic
sequence analysis of the producing strain revealed the genetic de-
terminants responsible for bacteriocin production. The amino
acid sequence of the cationic bacteriocin did not display signifi-
cant homology with previously characterized bacteriocins but in-
stead was found to be more similar to eukaryotic antimicrobial
peptides. Significantly, this small antimicrobial displayed broad-
spectrum antimicrobial activity and antistaphylococcal activity
comparable to that of the well-characterized lantibiotic lacticin
3147. Moreover, the wide distribution of bactofencin A among
L. salivarius isolates of porcine origin may be indicative of a host
species-specific trait. We also report the involvement of a DltB
homologue in a specific mechanism of bacteriocin immunity.
MATERIALS AND METHODS
Bacterial and fungal strains and culture conditions. The L. salivarius
strains used in this study are listed in Table 1. All lactobacilli were rou-
tinely cultured under anaerobic conditions at 37°C in MRS medium
(Difco Laboratories, Detroit, MI), unless otherwise stated. Anaerobic
conditions weremaintained with the use of anaerobic jars and Anaerocult
A gas packs (Merck, Darmstadt, Germany). The Escherichia coli, Crono-
bacter (Enterobacter), Listeria, and staphylococcal indicator strains em-
ployed for antimicrobial characterization (Table 1) were grown aerobi-
cally at 37°C in brain heart infusion (BHI) medium (Merck). E. coli XL-1
Blue, used as an intermediate host for DNA manipulations, was also
grown aerobically at 37°C in LB medium (Merck). Chloramphenicol
(Sigma, Poole, United Kingdom) was used in selective medium, being
added at concentrations of 20 g ml1 (Escherichia coli) and 5 g ml1
(Staphylococcus aureus, L. monocytogenes, and L. salivarius strains). The
indicator strains employed for antifungal characterization included Sac-
charomyces cerevisiae, Aspergillus niger, Botrytis cinerea, Geotrichium can-
didum, Penicillium notatum, and Rhizopus stolonifer. These were main-
tained aerobically on potato dextrose medium (Merck) at 25°C.
Purification of the hydrophilic antimicrobial peptide produced by
L. salivarius DPC6502. The antimicrobial peptide was purified from a
2-liter overnight culture of L. salivariusDPC6502 grown inMRSmedium.
The cells were removed by centrifugation at 8,000 g for 15min, and the
TABLE 1 Bacterial strains used in this study
Strain Relevant features Reference
Lactobacillus salivarius UCC118, Abp118 producer, human intestinal isolate 19
Lactobacillus salivarius DPC6502, bactofencin A producer, porcine intestinal isolate 27
Lactobacillus salivarius DPC6005, salivaricin P producer, bactofencin A producer, porcine
intestinal isolate
4
Lactobacillus salivarius 7.3 Salivaricin P producer, bactofencin A producer, porcine intestinal isolate 4
Lactobacillus salivarius DPC6189 Salivaricin P producer, bactofencin A producer, porcine intestinal isolate 4
Lactobacillus salivarius DPC6027 Salivaricin P producer, bactofencin A producer, porcine intestinal isolate 4
Lactobacillus salivarius DPC6488 Salivaricin T producer, human intestinal isolate 27
Lactobacillus salivarius DPC6196 Bac, despite harboring bacteriocin structural genes, human intestinal isolate 4
Lactobacillus salivarius DPC6095 Bac, human intestinal isolate
Lactobacillus salivarius DPC6107 Bac, human intestinal isolate
Escherichia coli XL-1 blue Intermediate host for DNA manipulations Stratagene
Microbial indicator strains
Escherichia coli DH5
Escherichia coli O157:H7 strain P1432, nontoxigenic 62
Cronobacter (Enterobacter) sakazakii NCTC08155 63
Listeria innocua DPC3572 Nonpathogenic 27
Listeria monocytogenes NCTC11994 46
Salmonella enterica serovar Typhimurium DT104 27
Staphylococcus aureus DPC5246 Mastitis isolate 45
Staphylococcus aureus DPC5646 Methicillin resistant 64
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supernatant applied to a column containing 90ml SP Sepharose fast-flow
cation-exchange resin (GE Healthcare, United Kingdom) previously
equilibrated with 20mMpotassium phosphate buffer, pH 2.5, containing
25% acetonitrile. The column was washed with 20 mM potassium phos-
phate buffer, pH 2.5, containing 25% acetonitrile, 600 mM KCl, and the
bioactive peptide was subsequently eluted from the column using 20 mM
potassium phosphate buffer, pH 2.5, containing 25% acetonitrile, 1 M
KCl. Acetonitrile was removed by rotary evaporation before the sample
was applied to a 5-g Strata-E C18 SPE column (Phenomenex, Cheshire,
United Kingdom) preequilibrated with methanol and water. The column
waswashedwith distilledwater, and the peptide elutedwith 70% (vol/vol)
propan-2-ol containing 0.1% (vol/vol) trifluoroacetic acid (TFA). The
propan-2-ol was removed by rotary evaporation, and 2- by 4-ml aliquots
of the resultant preparation were applied to a Jupiter proteo reversed-
phase high-performance liquid chromatography (RP-HPLC) column
(250.0 by 10.0mm, 4-mparticle size, 90-Å pore size; Phenomenex). The
column was preequilibrated with 10% (vol/vol) acetonitrile containing
0.1% (vol/vol) TFA, followed by separation and elution of the bioactive
peptide by gradient RP-HPLC using 0.1% (vol/vol) TFA and acetonitrile
concentrations that ranged from 10% to 30% (vol/vol), over a period of 5
to 45 min at a flow rate of 2.5 ml min1. Absorbance was monitored at a
wavelength of 214 nm.
Bacteriocin activity was monitored throughout the purification pro-
cedure by well diffusion assay using the sensitive indicator strain Lactoba-
cillus delbrueckii subsp. bulgaricus LMG6901. MALDI-TOF MS (Axima-
TOF2; Shimadzu Biotech, Manchester, United Kingdom) analysis was
performed on bioactive fractions as described previously (48). Fractions
of interest were further purified by reapplying them to the RP-HPLC
columnunder the conditions described above. N-terminal sequence anal-
ysis of the purified antimicrobial peptide by Edman degradation was per-
formed by Aberdeen Proteomics (University of Aberdeen, Scotland). Re-
duction and alkylation of the cysteine residueswere performed usingDTT
and iodoacetamide (Sigma).
Genome sequencing and analysis.The sequence of the genomicDNA
extracted from L. salivarius DPC6502 was determined through random
shotgun pyrosequencing (Beckman Coulter Genomics, United States).
The draft genome assembly was processed using the annotation software
package GAMOLA (49). The gene model was determined with Gene Lo-
cator and Interpolated Markov ModelER (GLIMMER) 3.02 (50). Se-
quence similarity analyses were performed using the gapped BLASTp al-
gorithmand the nonredundant database provided byNCBI (ftp://ftp.ncbi
.nih.gov/blast/db) (51). The Artemis Comparison Tool (ACT) (52)
facilitated comparative analysis of the draft genome assembly of L. sali-
varius DPC6502 with the complete genome sequence of L. salivarius
UCC118 (28). The genome annotation was manually verified also using
the ARTEMIS package. Global whole-genome and megaplasmid align-
ments were performed using stretcher, available at the EMBOSS server
(http://emboss.sourceforge.net/) (53).
Generation of a synthetic analogue of bactofencin A. The bactofen-
cin A peptide was synthesized according to the deduced amino acid se-
quence of the chromosomally located bacteriocin structural gene
(DLSL_0050) using microwave-assisted solid-phase peptide synthesis
(MW-SPPS) performed on a CEMLibertymicrowave peptide synthesizer
using an H-Cys-HMPB-ChemMatrix resin (PCAS Biomatrix, Inc., Que-
bec, Canada). The synthetic peptide was purified by RP-HPLC as de-
scribed above. Fractions containing a peptide with the desired molecular
mass, as identified by MALDI-TOF MS, were pooled and lyophilized us-
ing a Genevac HT 4 evaporator (Genevac Ltd., Ipswitch, United King-
dom). The peptide was dissolved in 70% (vol/vol) propan-2-ol at a con-
centration of 5 mg ml1 and stored at 20°C. Appropriate dilutions of
the peptide in 50 mM potassium phosphate buffer, pH 6.8, were used to
determine the specific activity of the synthetic analogue.
Specific activity determination. A microtiter plate assay system was
used to determine the MIC50 values of the synthetic bactofencin A ana-
logue for a range of pathogenic indicator strains (Table 1). Themicrotiter
plate was first treated with bovine serum albumin (BSA) to prevent ad-
herence of the peptide to the sides of the wells, as described previously
(54). Each plate included triplicate assays at each concentration of syn-
thetic bactofencin A examined. Each well contained a total volume of
200l, comprised of purified bactofencin A, the first component added to
the well, and 150 l of a 1-in-10 dilution of the indicator culture (A590 of
0.1) in BHI broth. Control wells contained medium only (blanks) and
untreated indicator culture. The microtiter plate cultures were incubated
at 37°C for 24 h, and the optical densities at 590 nm (OD590) recorded at
30-min intervals (GENios plus; Tecan, Switzerland). Triplicate readings
were averaged, and blanks were subtracted from these readings. The
amount of bacteriocin that inhibited the indicator strain by 50% was
defined as 50% of the final OD590 reading 0.05 of the untreated control
culture.
To determine whether the antimicrobial activity of bactofencin A is
bactericidal or bacteriostatic in nature, the effect of bactofencin A on
S. aureus DPC5246 was further investigated. Three independent cultures
of S. aureus DPC5246 were grown overnight at 37°C. 3 replicate 1-ml
volumes of sterile double-strength BHI broth medium were inoculated
with the test organism to give initial cell numbers of approximately
106 CFU/ml. Bactofencin A was added, and the volume made up to 2 ml
with sterile distilled water. The bacteriocin was omitted from the control
and its volume replaced with sterile water. Samples were removed at in-
tervals, serially diluted, plated on BHI agar, and then incubated aerobi-
cally at 37°C.
DNA manipulations, transformation, and plasmid construction.
The DltB homologue encoded by DLSL_0051, designated bfnI, was am-
plified by routine PCR using velocity DNA polymerase (Bioline, United
Kingdom) and the primer pair bfnIF, 5= CGGGGTACCCCAGGAATGT
ATCGTTGGTGC 3=, and bfnIR, 5= CGAGCTCGTTACATACAATTGCA
ACCATAC 3=, containing the restriction sites for the KpnI and SacI en-
zymes (underlined). Digestion facilitated insertion of the resultant
product downstream from the constitutive p44 lactococcal promoter in
the expression vector pNZ44 (55) to generate pEOS01. The integrity of
the insert was confirmed by DNA sequencing using the primer pair
pNZ44_for, 5= TTACAGGTACATCATTCTGTTTGT 3=, and pNZ44_rev,
5= TGTTTTAACGATTATGCCGATAAC 3=, specific for the pNZ44 mul-
tiple cloning site (56). Restriction enzymes and T4DNA ligase (New Eng-
land Biolabs, Beverly, MA) were used according to the manufacturer’s
instructions. PCR products were purified using the Isolate PCR and gel kit
(Bioline), and the Qiagen plasmid minikit (Qiagen, West Sussex, United
Kingdom) was used to isolate plasmid DNA from E. coli transformants.
E. coli, S. aureus, L. monocytogenes, and L. salivarius were transformed by
electroporation in accordance with methods described previously (57–
60). The sensitivities of the clones were compared to those of the control
strains using the microtiter well-based assay system described above and
also by well diffusion assay using 2-fold serial dilutions of bactofencin A
prepared in 50 mM potassium phosphate buffer, pH 6.8. Similarly, the
clones and their respective controls were assayed against the cationic an-
timicrobial peptides magainin II, polymyxin B, protegrin-1, -polylysine,
and nisin, as well as gramicidin D, an antimicrobial of neutral charge.
Comparison of relative net cell surface charges. The cytochrome c
binding affinity of the bfnI clones and their respective isogenic controls
were measured as described previously (32). Briefly, mid-log-phase cells
(with an OD600 of 0.5) were harvested and washed twice with 20 mM
MOPS (morpholinepropanesulfonic acid), pH 7. The cells were then re-
suspended in 0.5 ml 20 mMMOPS, pH 7, and cytochrome c from equine
heart (Sigma) was added at a final concentration of 0.5 mg ml1. Follow-
ing a 10-min incubation at room temperature, the cells were pelleted and
the unbound cytochrome c present in the supernatant was quantified
spectrophotometrically at 530 nm. A control consisting of 0.5 mg ml1
cytochrome c in 20 mM MOPS, pH 7 (buffer without cells), was also
included as a reference. The absorbance measurements obtained com-
pared with that of the reference were calculated as the absorption ratios
(reflecting the bacterial surface charge). A dltA-deficient S. aureus Sa113
Bactofencin A, a Defensin-Like Bacteriocin
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mutant and the corresponding parent strain (32) served as experimental
controls. The data are representative of at least three independent studies.
Detection of bfnA. The presence of bfnA was determined by PCR
using template DNA from eight additional genetically distinct intestinal
L. salivarius isolates (Table 1) and the primer pair bfnAF, 5= CAGTCGAC
AATGATCATGATGGAGTAGCG 3=, and bfnAR, 5= GGAAGTAAGTAG
GGTTTTGATAAGGTGTC 3=, to amplify a product of 430 nucleotides.
This was performed using the Expand high-fidelity PCR system (Roche)
according to the manufacturer’s instructions. The products derived from
PCR were purified and sequenced (Beckman Coulter Genomics), and
analysis of DNA sequence data was performed using Lasergene 8 software
(DNASTAR, Inc.,Madison,WI). TemplateDNAofL. salivariusDPC6502
and L. salivarius UCC118 were used as positive and negative controls,
respectively. Subsequent purification and MS analyses, as described
above, further confirmed positive results.
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